js001

Key facts

Mechanism of action

Programmed cell death protein 1 antagonist

Primary target: Programmed cell death protein 1

Approval history

1. JS001 Phase 3 · Shanghai University of · Triple-Negative Breast Cancer
2. Toripalimab Phase 2 · First People's Hospital · Locally Advanced Colon Cancer
3. Clopidogrel Approved · Chinese Academy of · Coronary Artery Disease
4. Renin-angiotensin system blockers Approved · Hospital Authority · Diabetes

1. cemiplimab Antineoplastic and immunomodulating agents (L01)
2. cemiplimab-rwlc Programmed cell death protein 1 inhibitor
3. tislelizumab Antineoplastic and immunomodulating agents (L01)
4. toripalimab-tpzi Programmed cell death protein 1 antagonist
5. dostarlimab-gxly Programmed cell death protein 1 antagonist
6. islelizumab-jsgr Programmed cell death protein 1 inhibitor

Frequently asked questions